| Literature DB >> 35631137 |
Dejan Reljic1,2, Walburga Dieterich1,2, Hans J Herrmann1,2, Markus F Neurath2,3, Yurdagül Zopf1,2.
Abstract
Exercise is a cornerstone in metabolic syndrome (MetS) treatment. However, the effects of low-volume exercise modalities on MetS-associated low-grade inflammation are unclear. A total of 106 MetS patients (53.7 ± 11.4 years) were randomized to low-volume high-intensity interval training (LOW-HIIT, 14 min/session), single-set resistance training (1-RT, ~15 min/session), whole-body electromyostimulation (WB-EMS, 20 min/session), three-set resistance training (3-RT, ~50 min/session), each performed 2 ×/week for 12 weeks, or a control group (CON). All groups received nutritional counseling for weight loss. Inflammatory and cardiometabolic indices were analyzed pre- and post-intervention. All groups significantly reduced body weight by an average of 3.6%. Only LOW-HIIT reduced C-reactive protein (CRP) (-1.6 mg/L, p = 0.001) and interleukin-6 (-1.1 pg/mL, p = 0.020). High-sensitivity CRP and lipopolysaccharide-binding protein decreased following LOW-HIIT (-1.4 mg/L, p = 0.001 and -2.1 ng/mL, p = 0.004) and 3-RT (-0.6 mg/L, p = 0.044 and -2.0 ng/mL, p < 0.001). MetS severity score improved with LOW-HIIT (-1.8 units, p < 0.001), 1-RT (-1.6 units, p = 0.005), and 3-RT (-2.3 units, p < 0.001). Despite similar effects on body weight, low-volume exercise modalities have different impact on inflammatory and cardiometabolic outcomes in MetS patients. LOW-HIIT has superior efficacy for improving inflammation compared to 1-RT and WB-EMS. Resistance-based exercise appears to require a higher volume to promote beneficial impact on inflammation.Entities:
Keywords: CRP; cardiometabolic health; high-intensity interval training; obesity; single-set resistance training; whole-body electromyostimulation
Mesh:
Year: 2022 PMID: 35631137 PMCID: PMC9145085 DOI: 10.3390/nu14101996
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Baseline characteristics of all included patients.
| Variable | LOW-HIIT ( | 1-RT ( | 3-RT ( | WB-EMS ( | CON ( |
|---|---|---|---|---|---|
| Gender (f/m) | 10/16 | 16/6 | 15/10 | 18/8 | 18/8 |
| Age (years) | 50.6 ± 11.3 | 55.2 ± 12.1 | 52.7 ± 11.5 | 52.7 ± 12.5 | 49.0 ± 15.1 |
| BMI (kg/m2) | 37.8 ± 6.6 | 36.8 ± 7.4 | 40.1 ± 9.0 | 37.2 ± 4.0 | 38.0 ± 6.3 |
| CRP (mg/L) | 5.0 ± 3.4 | 6.1 ± 5.8 | 5.7 ± 6.3 | 4.1 ± 2.8 | 4.2 ± 3.3 |
| MetS z-score | 2.9 ± 3.9 | 3.4 ± 4.8 | 3.3 ± 4.3 | 2.6 ± 2.3 | 2.2 ± 3.1 |
Values are shown as mean ± SD. f = females, m = males, BMI = body mass index, CRP = C-reactive protein, MetS z-score = metabolic. syndrome z-score.
Figure 1Study flow chart.
Daily nutritional intakes before the intervention and during the last week of intervention.
| Variable | LOW-HIIT ( | 1-RT ( | 3-RT ( | WB-EMS ( | CON ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Energy (kcal/day) | 2228 ± 896 | 1974 ± 801 | 2342 ± 907 | 1673 ± 520 a | 2344 ± 622 | 1769 ± 514 b | 2418 ± 695 | 1916 ± 415 b | 2237 ± 856 | 1798 ± 783 |
| Protein (g/day) | 92 ± 46 | 90 ± 31 | 102 ± 46 | 78 ± 28 a | 108 ± 41 | 80 ± 27 b | 96 ± 30 | 89 ± 31 | 94 ± 30 | 82 ± 33 |
| Protein (g/kg/day) | 0.8 ± 0.3 | 0.8 ± 0.3 | 0.9 ± 0.3 | 0.7 ± 0.3 | 1.0 ±0.4 | 0.8 ± 0.3 | 1.0 ± 0.5 | 0.8 ± 0.3 | 1.0 ± 0.3 | 0.9 ± 0.3 |
| Fat (g/day) | 89 ± 41 | 77 ± 36 | 97 ± 40 | 71 ± 28 | 96 ± 31 | 72 ± 26 b | 99 ± 40 | 80 ± 19 | 99 ± 57 | 70 ± 43 |
| Fat (g/kg/day) | 0.8 ± 0.3 | 0.7 ± 0.3 | 1.0 ± 0.4 | 0.8 ± 0.3 | 1.0 ± 0.4 | 0.8 ± 0.4 | 0.9 ± 0.4 | 0.8 ± 0.3 | 1.0 ± 0.5 | 0.7 ± 0.5 |
| CHO (g/day) | 216 ± 97 | 206 ± 92 | 237 ± 92 | 160 ± 51 b | 216 ± 58 | 170 ± 52 b | 249 ± 82 | 184 ± 61 a | 210 ± 76 | 180 ± 84 |
| CHO (g/kg/day) | 1.9 ± 0.7 | 1.8 ± 0.8 | 2.4 ± 0.7 | 1.8 ± 0.7 a | 2.4 ± 0.8 | 1.7 ± 0.7 b | 2.0 ± 0.7 | 1.6 ± 0.6 a | 2.1 ± 0.9 | 1.9 ± 1.0 |
| Fibres (g/day) | 23 ± 9 | 23 ± 11 | 24 ± 11 | 21 ± 8 | 23 ± 7 | 19 ± 7 | 22 ± 10 | 18 ± 7 | 24 ± 13 | 23 ± 10 |
Values are shown as mean ± SD. CHO = carbohydrates. a (p < 0.05), b (p < 0.01): significant difference versus pre-intervention.
Figure 2Changes in serum concentrations of C-reactive protein (A), high-sensitivity C-reactive protein (B), interleukin-6 (C), lipopolysaccharide-binding protein (D), and changes in MetS z-score (E) and body weight (F). a (p < 0.05), b (p < 0.01), c (p < 0.001): significant difference versus pre-intervention; * (p < 0.05), ** (p < 0.01): significant difference versus CON; ++ (p < 0.01): significant difference versus WB-EMS.
Anthropometric and body composition data before and after the intervention.
| Variable | LOW-HIIT ( | 1-RT ( | 3-RT ( | WB-EMS ( | CON ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Weight (kg) | 117.0 ± 26.1 | 113.0 ± 25.2 c | 102.9 ± 27.7 | 98.1 ± 26.0 b | 114.0 ± 30.1 | 110.3 ± 30.1 c | 106.1 ± 17.9 | 101.9 ± 14.6 c | 104.4 ± 20.5 | 101.5 ± 21.5 c |
| BMI (kg/m2) | 37.8 ± 6.6 | 36.5 ± 6.4 c | 36.5 ± 7.4 | 34.8 ± 7.1 b | 38.8 ± 8.1 | 37.5 ± 7.5 b | 37.3 ± 4.1 | 35.9 ± 3.2 c | 36.6 ± 5.2 | 35.5 ± 5.5 c |
| FM (kg) | 49.8 ± 14.8 | 46.3 ± 14.3 c,* | 47.7 ± 16.1 | 43.9 ± 14.8 b | 51.8 ± 16.6 | 48.0 ± 16.1 c,* | 46.0 ± 8.2 | 43.1 ± 6.1 b | 47.8 ± 11.5 | 45.7 ± 12.7 |
| FM (%) | 42.3 ± 7.6 | 40.7 ± 8.1 c,* | 45.8 ± 5.4 | 44.2 ± 5.7 b | 45.3 ± 6.6 | 43.3 ± 7.3 c,* | 43.6 ± 5.1 | 42.6 ± 5.0 b | 46.1 ± 7.0 | 44.9 ± 7.5 |
| SMM (kg) | 33.3 ± 9.0 | 32.8 ± 8.9 | 26.5 ± 7.8 | 25.8 ± 7.8 | 30.7 ± 10.4 | 30.6 ± 10.6 | 29.2 ± 7.0 | 28.3 ± 6.3 b | 27.5 ± 7.9 | 26.9 ± 7.9 c |
| TBW (L) | 50.0 ± 11.7 | 49.5 ± 11.7 | 41.6 ± 9.9 | 40.8 ± 9.9 | 46.7 ± 12.4 | 46.7 ± 12.8 c | 44.8 ± 9.1 | 43.9 ± 9.1 | 44.8 ± 10.8 | 43.9 ± 10.5 |
| Waist (cm) | 116 ± 19 | 110 ± 18 c,* | 111 ± 16 | 106 ± 14 c | 116 ± 18 | 111 ± 17 c,* | 114 ± 10 | 111 ± 9 b | 109 ± 11 | 107 ± 11 |
Values are shown as mean ± SD. BMI = body mass index, FM = fat mass, SMM = skeletal muscle mass, TBW = total body water. b (p < 0.01), c (p < 0.001): significant difference versus pre-intervention; * (p < 0.01): significant difference versus CON.
Inflammatory markers before and after the intervention.
| Variable | LOW-HIIT ( | 1-RT ( | 3-RT ( | WB-EMS ( | CON ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| CRP (mg/L) # | 5.0 ± 3.4 | 3.4 ± 2.7 b,* | 4.7 ± 4.8 | 4.5 ± 4.7 | 4.0 ± 3.3 | 3.7 ± 2.9 | 3.8 ± 2.4 | 3.4 ± 2.4 b | 3.9 ± 2.7 | 5.4 ± 8.0 |
| hsCRP (mg/L) # | 4.1 ± 3.1 | 2.7 ± 2.3 b,* | 4.0 ± 4.6 | 3.8 ± 4.6 | 3.3 ± 3.2 | 2.7 ± 2.5 a | 2.9 ± 2.0 | 2.6 ± 2.1 | 3.1 ± 2.4 | 4.4 ± 7.3 |
| IL-1β (pg/mL) | 6.3 ± 4.3 | 6.4 ± 3.8 | 9.7 ± 8.4 | 11.8 ± 9.8 | 9.8 ± 5.6 | 10.7 ± 6.5 | 10.0 ± 5.6 | 11.1 ± 8.3 | 6.7 ± 4.1 | 6.2 ± 3.8 |
| IL-6 (pg/mL) | 3.6 ± 3.0 | 2.5 ± 1.6 a | 2.8 ± 1.6 | 2.6 ± 1.7 | 2.6 ± 1.1 | 2.6 ± 1.6 | 2.5 ± 1.3 | 2.3 ± 1.2 | 3.1 ± 1.6 | 3.4 ± 3.0 |
| IFNγ (pg/mL) | 9.5 ± 6.8 | 8.8 ± 4.2 | 7.0 ± 4.1 | 6.4 ± 4.4 | 10.3 ± 9.4 | 9.1 ± 9.0 | 7.4 ± 2.9 | 7.2 ± 3.2 | 8.1 ± 4.5 | 7.5 ± 4.3 |
| Adiponectin [µ/mL) | 2.3 ± 1.3 | 2.2 ± 1.2 | 3.8 ± 2.7 | 3.9 ± 3.1 | 3.6 ± 3.0 | 3.2 ± 2.3 | 2.5 ± 1.5 | 2.4 ± 1.2 | 2.6 ± 1.3 | 2.6 ± 1.3 |
| LBP (ng/mL) # | 13.2 ± 2.5 | 11.1 ± 3.1 b,*,§ | 29.1 ± 7.6 | 28.0 ± 7.1 | 28.2 ± 3.6 | 26.3 ± 5.6 c | 23.6 ± 5.8 | 23.5 ± 5.8 | 16.9 ± 8.9 | 17.0 ± 9.4 |
Values are shown as mean ± SD. CRP = C-reactive protein, hsCRP = high-sensitivity C-reactive protein, IL-1 = interleukine-1, hsIL-6 = high-sensitivity inter-leukine-6, INFα = interferone-alpha, LBP = lipopolysaccharide-binding protein. a (p < 0.05), b (p < 0.01), c (p < 0.001): significant difference versus pre-intervention; * (p < 0.05): significant difference vs. CON; § (p < 0.001): significant difference versus 1-RT, 3-RT, WB-EMS; # (p < 0.05): significant group-by-time interaction.
Cardiovascular disease risk distribution related to hsCRP concentrations before and after the intervention.
| Variable | LOW-HIIT ( | 1-RT ( | 3-RT ( | WB-EMS ( | CON ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Low risk | 1 (3.8) | 6 (23.1) | 4 (23.5) | 6 (35.3) | 3 (15.8) | 4 (21.1) | 3 (15.0) | 3 (15.0) | 1 (4.5) | 3 (13.6) |
| Intermediate risk | 10 (38.5) | 13 (50.0) | 6 (25.3) | 3 (17.6) | 6 (31.6) | 7 (36.8) | 9 (45.0) | 10 (50.0) | 13 (59.1) | 8 (36.4) |
| (1–3 mg/L) | ||||||||||
| High risk | 15 (57.7) | 7 (26.9) | 7 (41.2) | 8 (47.1) | 7 (52.6) | 8 (42.1) | 8 (40.0) | 7 (35.0) | 8 (36.4) | 11 (50.0) |
| (>3 mg/L) | ||||||||||
Values are shown as total numbers and percentages in parentheses. Cardiovascular risk grading according to Cardoso and Paulos [60].
Cardiometabolic markers before and after the intervention.
| Variable | LOW-HIIT ( | 1-RT ( | 3-RT ( | WB-EMS ( | CON ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| VO2max (mL/kg/min) # | 22.6 ± 5.5 | 25.6 ± 5.6 c,+ | 21.0 ± 5.4 | 22.2 ± 4.6 | 21.0 ± 5.1 | 22.0 ± 4.3 | 21.0 ± 5.7 | 21.7 ± 5.4 | 20.6 ± 7.4 | 20.2 ± 7.9 |
| MetS z-score # | 2.9 ± 3.8 | 1.1 ± 3.0 c,+ | 2.1 ± 3.8 | 0.5 ± 3.0 b | 2.8 ± 4.1 | 0.5 ± 3.9 c,+ | 2.3 ± 2.3 | 1.8 ± 2.3 | 2.0 ± 3.1 | 1.3 ± 3.0 |
| SBP (mmHg) # | 144 ± 17 | 133 ± 11 c | 148 ± 17 | 138 ± 12 | 142 ± 17 | 132 ± 16 b | 134 ± 14 | 137 ± 11 | 138 ± 13 | 137 ± 11 |
| DBP (mmHg) # | 94 ± 11 | 86 ± 8 c | 92 ± 16 | 87 ± 10 | 87 ± 9 | 83 ± 9 b | 86 ± 9 | 88 ± 10 | 89 ± 9 | 87 ± 7 |
| MAB (mmHg) # | 111 ± 11 | 102 ± 7 c | 111 ± 14 | 104 ± 9 a | 106 ± 11 | 99 ± 11 b | 102 ± 9 | 104 ± 9 | 105 ± 9 | 104 ± 7 |
| Glucose (mg/dL) | 101 ± 18 | 100 ± 12 | 96 ± 16 | 96 ± 12 | 105 ± 13 | 99 ± 14 a | 104 ± 12 | 102 ± 14 | 98 ± 15 | 95 ± 16 |
| Triglycerides (mg/dL) | 132 ± 56 | 128 ± 44 | 126 ± 43 | 119 ± 28 | 146 ± 89 | 124 ± 56 a | 133 ± 59 | 118 ± 36 | 148 ± 73 | 130 ± 64 |
| Cholesterol (mg/dL) | 214 ± 33 | 213 ± 35 | 228 ± 29 | 218 ± 33 | 227 ± 55 | 216 ± 45 b | 217 ± 35 | 210 ± 31 | 235 ± 42 | 222 ± 33 a |
| HDL (mg/dL) | 49 ± 10 | 48 ± 11 | 59 ± 19 | 59 ± 18 | 59 ± 17 | 58 ± 15 | 53 ± 14 | 52 ± 13 | 56 ± 12 | 54 ± 12 |
| LDL (mg/dL) | 144 ± 27 | 143 ± 27 | 148 ± 23 | 138 ± 22 a | 144 ± 39 | 137 ± 34 | 143 ± 28 | 137 ± 24 | 154 ± 33 | 147 ± 26 |
Values are shown as mean ± SD. SBP = systolic blood pressure, DBP = diastolic blood pressure, MAB = mean arterial blood pressure, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, LBP = lipopolysaccharide-binding protein. a (p < 0.05), b (p < 0.01), c (p < 0.001): significant difference versus pre-intervention; + (p < 0.05): significant difference versus WB-EMS and CON; # (p < 0.01): significant group-by-time interaction.